The PAPZIMEOS launch is accelerating faster than expected, with Q1 revenue already exceeding the prior quarter's full-year total. The permanent J-code taking effect in April should further boost site activations and patient starts in Q2. Watch for continued revenue growth and progress toward cash flow break-even by year-end. The upcoming ASCO presentation (May 29-June 2) may provide additional catalyst on durability data.
Price Chart
Executive Summary
Precigen reported Q1 2026 revenue of $23.3M, massively up from $1.3M a year ago, driven by $21.6M in PAPZIMEOS product revenue in its first full commercial quarter. Net loss narrowed to $7.9M ($0.02/share) from $54.2M ($0.18/share) in Q1 2025, as the company transitions to a commercial-stage biopharma. The strong launch trajectory and cash position of $56.7M support management's expectation of reaching cash flow break-even by end of 2026.
Key Financial Metrics
Key Facts
- Q1 2026 total revenue of $23.3M, up from $1.3M in Q1 2025, driven by $21.6M in PAPZIMEOS net product revenue
- Net loss narrowed to $7.9M ($0.02/share) from $54.2M ($0.18/share) in Q1 2025
- Cash, cash equivalents, and investments totaled $56.7M as of March 31, 2026
- Approximately $25.7M in PAPZIMEOS-related accounts receivable not yet collected as of quarter-end
- Company expects current cash plus anticipated PAPZIMEOS revenue to fund operations to cash flow break-even by end of 2026
- Patient hub enrollment surpassed 400 patients, with 25% from community settings
- Permanent J-code (J3404) effective April 1, 2026, expected to further streamline reimbursement and site activations
Financial Impact
Q1 2026 product revenue of $21.6M vs $0.2M in Q1 2025; net loss improved by $46.3M year-over-year
Risk Factors
- Dependence on single product PAPZIMEOS for revenue; any commercial disruption would be material
- Cash burn remains significant; break-even timeline depends on continued revenue acceleration
- Long-term debt of $93.5M adds financial leverage and interest expense
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000950103-26-007158 |
| Document: dp246650_8k.htm | 0000950103-26-007158 |
| Document: 0000950103-26-007158-index-headers.html | 0000950103-26-007158 |
| Document: 0000950103-26-007158-index.html | 0000950103-26-007158 |
| Document: 0000950103-26-007158.txt | 0000950103-26-007158 |
| 8-K Data (Synthetic) | 0000950103-26-007158 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 29, 2026 4w ago | Insider Cluster | $6.93 $7.94 | ▲ +14.57% | ▲ +14.51% | $8.30 (+19.70%) |
Aug 26, 2026 5w ago | 144 | $7.19 $7.70 | ▲ +7.09% | ▲ +7.60% | $8.30 (+15.37%) |
Aug 25, 2026 5w ago | Insider Cluster | $7.42 $7.70 | ▼ −3.77% | ▼ −3.55% | $8.30 (−11.79%) |
Aug 25, 2026 5w ago | Insider Cluster | $7.42 $7.70 | ▲ +3.77% | ▲ +3.55% | $8.30 (+11.79%) |
Aug 7, 2026 7w ago | Insider Cluster | $7.00 $6.87 | ▼ −1.86% | ▼ −0.94% | $8.30 (+18.50%) |
Aug 3, 2026 8w ago | Insider Cluster | $6.53 $6.86 | ▲ +5.05% | ▲ +6.29% | $8.30 (+27.03%) |
Jul 1, 2026 13w ago | Insider Cluster | $5.64 $5.94 | ▼ −5.32% | ▼ −5.73% | $8.30 (−47.07%) |
Jun 24, 2026 14w ago | 8-K | $5.52 $5.54 | ▲ +0.36% | ▼ −0.17% | $8.30 (+50.27%) |
Jun 1, 2026 17w ago | Insider Cluster | $3.86 $5.25 | ▲ +36.01% | ▲ +37.58% | $8.30 (+114.90%) |
Jun 1, 2026 17w ago | Insider Cluster | $3.86 $5.25 | ▲ +36.01% | ▲ +37.58% | $8.30 (+114.90%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access